What the Study Found (In Plain English)
Published in Progress in cardiovascular diseases (2024), this meta-analysis evaluating 11,502 human participants investigated: The Cardiovascular safety of testosterone replacement therapy (TRT) among men with hypogonadism is not well established to date. Key clinical takeaway: Our analysis indicates that for patients with hypogonadism, testosterone replacement therapy does not increase the CVD risk and all-cause mortality.
Dr. Lin (AI Evidence Lead): Statistical Endpoints & Numbers
Primary Endpoint & Quantitative Summary (Progress in cardiovascular diseases, 2024-01-15; N = 11502; Rigor 99/100): Our analysis indicates that for patients with hypogonadism, testosterone replacement therapy does not increase the CVD risk and all-cause mortality.
Study Limitations & Caveats Before You Act
Clinical trials evaluate specific inclusion/exclusion cohorts under protocol-controlled conditions (Meta-Analysis). Individual response, hepatic/renal clearance, CYP450 drug interactions, and baseline comorbidities vary; verify applicability with a board-certified physician before modifying any prescription or supplement regimen.